Back to top
more

Core Laboratories (CLB)

(Real Time Quote from BATS)

$20.35 USD

20.35
209,656

+0.35 (1.75%)

Updated Jun 28, 2022 02:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.75%
2Buy18.15%
3Hold9.70%
4Sell5.35%
5Strong Sell2.45%
S&P50010.91%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 251)

Industry: Oil and Gas - Field Services

Trades from $1

Balance Sheet

Research for CLB

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Core Laboratories NV falls in the month of December.

All items in Millions except Per Share data.

12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017
Assets          
Cash & Equivalents 18 14 11 13 14
Receivables 107 93 138 143 141
Notes Receivable 0 0 0 0 0
Inventories 45 38 50 46 33
Other Current Assets 19 21 22 29 19
Total Current Assets 189 166 221 231 207
Net Property & Equipment 111 115 124 123 123
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 70 73 67 11 11
Intangibles 108 108 231 232 188
Deposits & Other Assets 41 40 56 51 55
Total Assets 581 569 775 649 585
Liabilities & Shareholders Equity 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017
Notes Payable 0 0 0 0 0
Accounts Payable 30 23 36 41 42
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 27 33 35 30 36
Income Taxes Payable 7 8 6 3 1
Other Current Liabilities 15 14 23 28 26
Total Current Liabilities 91 90 112 103 105
Mortgages 0 0 0 0 0
Deferred Taxes/Income 24 21 27 8 5
Convertible Debt 0 0 0 0 0
Long-Term Debt 189 259 305 290 227
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 67 67 84 88 99
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 420 493 593 488 436
Shareholders Equity 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017
Preferred Stock 0 0 0 0 0
Common Stock (Par) 1 1 1 1 1
Capital Surplus 101 41 52 57 54
Retained Earnings 68 50 161 156 174
Other Equity -6 -3 -2 -1 -4
Treasury Stock 4 14 29 53 76
Total Shareholder's Equity 161 76 182 161 149
Total Liabilities & Shareholder's Equity 581 569 775 649 585
Total Common Equity 161 76 182 161 149
Shares Outstanding 46.20 44.50 44.30 44.20 44.10
Book Value Per Share 3.48 1.70 4.11 3.64 3.37

Fiscal Year End for Core Laboratories NV falls in the month of December.

All items in Millions except Per Share data.

3/31/2022 12/31/2021 9/30/2021 6/30/2021 3/31/2021
Assets          
Cash & Equivalents 22 18 19 34 28
Receivables 114 107 108 110 100
Notes Receivable 0 0 0 0 0
Inventories 48 45 44 39 39
Other Current Assets 18 19 16 18 19
Total Current Assets 202 189 187 201 186
Net Property & Equipment 110 111 113 112 113
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 68 70 73 70 68
Intangibles 107 108 108 108 108
Deposits & Other Assets 38 41 40 41 39
Total Assets 585 581 586 598 584
Liabilities & Shareholders Equity 3/31/2022 12/31/2021 9/30/2021 6/30/2021 3/31/2021
Notes Payable 0 0 0 0 0
Accounts Payable 34 30 35 30 26
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 31 27 27 28 28
Income Taxes Payable 6 7 5 7 7
Other Current Liabilities 16 15 14 13 13
Total Current Liabilities 100 91 93 91 86
Mortgages 0 0 0 0 0
Deferred Taxes/Income 23 24 24 21 20
Convertible Debt 0 0 0 0 0
Long-Term Debt 190 189 188 208 208
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 59 66 69 66
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 419 420 425 444 438
Shareholders Equity 3/31/2022 12/31/2021 9/30/2021 6/30/2021 3/31/2021
Preferred Stock 0 0 0 0 0
Common Stock (Par) 1 1 1 1 1
Capital Surplus 107 101 106 98 103
Retained Earnings 66 68 66 66 58
Other Equity -2 -6 -5 -6 -4
Treasury Stock 6 4 7 5 13
Total Shareholder's Equity 166 161 161 154 146
Total Liabilities & Shareholder's Equity 585 581 586 598 584
Total Common Equity 166 161 161 154 146
Shares Outstanding 46.30 46.20 46.20 46.30 46.30
Book Value Per Share 3.59 3.48 3.49 3.33 3.15